Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.

M C Jensen1, L J N Cooper, A M Wu

  • 1Division of Pediatric Hematology-Oncology, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA.

Cytotherapy
|May 15, 2003
PubMed
Summary

Genetically engineered T-cells (CTL) gain CD20 specificity to target lymphoma cells. This approach shows potential for enhancing immunotherapy in CD20-positive malignancies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Imaging study on the safety of axial pedicle screw placement by the position of the screw trajectory tip on the anteroposterior and lateral radiographs].

Zhonghua yi xue za zhi·2022
Same author

[Analysis of imaging features of age-related cerebral small vessel disease with idiopathic normal pressure hydrocephalus].

Zhonghua yi xue za zhi·2020
Same author

[Stereotactic biopsy in the accurate diagnosis of lesions in the brain stem and deep brain].

Zhonghua yi xue za zhi·2018
Same author

Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.

Leukemia·2016
Same author

Advances in PET Detection of the Antitumor T Cell Response.

Advances in immunology·2016

Area of Science:

  • Immunology
  • Oncology
  • Cellular Therapy

Background:

  • CD20-targeted antibody (Ab) therapies have advanced B-cell lymphoma immunotherapy.
  • Cellular immune responses can augment the efficacy of monoclonal antibody (MAb) treatments.

Purpose of the Study:

  • To genetically modify human cytotoxic T lymphocytes (CTL) to recognize and target CD20-expressing lymphoma cells.
  • To evaluate the therapeutic potential of engineered CTLs in B-cell lymphomas.

Main Methods:

  • Human T-cells were engineered to express a chimeric immunoreceptor (scFvFczeta) conferring CD20 specificity.
  • Transduction was achieved using naked DNA plasmid vectors via electroporation, followed by selection.

Main Results:

Related Experiment Videos

  • Engineered CTLs demonstrated HLA-unrestricted, CD20-specific lysis of lymphoma cells.
  • Activated CTLs produced Tc1 cytokines (IFN-gamma) and proliferated in response to CD20+ lymphoma cells.

    • Conclusions:

    • These findings support the clinical investigation of adoptive therapy using CD20-specific CTLs.
    • Engineered CTLs represent a promising component for immunotherapy of CD20+ malignancies.